Verve Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Verve Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Verve Therapeutics Inc
Rating: 1.47629175
Author: Trendlyne DVM scores

Momentum Trap

about

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradi...

11.09 -0.04 (-0.36%)

Near 52W High of $11.40

2.6M

XNAS Volume

XNAS 09 Jul, 2025 5:30 PM (EDT)

Low Financial Strength

16.7 / 100

Expensive Valuation

13.5 / 100

Technically Bullish

71.3 / 100

Momentum Trap These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked. View Similar Embed DVM

1Yr Price target upside is 36%

8 analysts

Verve Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Verve Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradi...

Near 52W High of $11.40

SWOT Analysis

Verve Therapeutics Inc Live Price Chart